The Haemostasis Section focuses on the diagnosis and treatment of disorders of blood coagulation and this is realised through two core activities, standardisation and product testing, under-pinned by collaborative research and development activities.  The provision of WHO International Standards is a core function supporting the accurate estimation of blood coagulation factors and related therapeutics required for the diagnosis of disease (eg. Haemophilia A and B) and the potency labelling of therapeutics such as coagulation factor concentrates (eg. factor VIII, factor IX), antithrombotics (eg. Low Molecular Weight Heparin) and thrombolytic drugs (eg. Streptokinase, Tissue Plasminogen Activator).  The Section plays a major role in therapeutic product testing related to the Institute’s statutory function as a European Official Medicines Control Laboratory (OMCL) for plasma-derived products (eg. Coagulation factor concentrates, Virus-inactivated fresh, frozen plasma, Fibrin sealants) as well as collaborating with manufacturers and academia in the evaluation of new therapeutics under development.